This review critically examines the evolution of treatment strategies for HER2-positive mBC, focusing on first-line treatment selection, maintenance, CNS management, post-T-DXd sequencing, long responders, mechanisms of resistance and biomarker development.
M. Palleschi, A. Viansone, Filippo Merloni et al.· Cancer Treatment Reviews· 0 citations
OBJECTIVE
As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC.
METHODS
Data from phase II...
V. Tuninetti, A. Farolfi, Simona Butticè et al.· Tumori· 0 citations
Conclusively, single‐CTC analysis enables comprehensive characterization of the PI3K/AKT/PTEN pathway, revealing molecular heterogeneity and capturing events not detectable by tumor tissue or ctDNA.
T. Rossi, M. Palleschi, C. Gianni et al.· Cancer Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
